Cdmo Services
Skip to main content

Explore about our broad range of CDMO Services and Products

Pipeline

KD Biopharma has different projects under assessment and is currently in the process of conducting Phase III of an orphan Drug named Alfa® indicated for the treatment of Familial Adenomatous Polyposis (FAP)

Alfa® has also shown to effectively help Ulcerative Colitis (UC) and Sporadic Polyps (SP) patients to keep the disease under control.

Product candidate (Pathway)Potencial indicationsDiscoveryPreclinicalPhase 1Phase 2Phase 3
Alfa®FAP     
Alfa®UC     
Alfa®SP